Protocol Ledger

NCT06140524 · Phase II · RECRUITING

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-Hig

Interventional Phase II clinical trial protocol NCT06140524 sponsored by Regeneron Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-16 Enrollment: 116 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06140524
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)116 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06140524
Protocol FieldVerified Registry Value
NCT IdentifierNCT06140524
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment116 participants (ESTIMATED)
Registered Start Date2024-09-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI